252 related articles for article (PubMed ID: 30715161)
1. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Condorelli R; Mosele F; Verret B; Bachelot T; Bedard PL; Cortes J; Hyman DM; Juric D; Krop I; Bieche I; Saura C; Sotiriou C; Cardoso F; Loibl S; Andre F; Turner NC
Ann Oncol; 2019 Mar; 30(3):365-373. PubMed ID: 30715161
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
Huang CC; Tsai YF; Liu CY; Chao TC; Lien PJ; Lin YS; Feng CJ; Chiu JH; Hsu CY; Tseng LM
BMC Cancer; 2021 Feb; 21(1):199. PubMed ID: 33632156
[TBL] [Abstract][Full Text] [Related]
3. Precision medicine in breast cancer: From clinical trials to clinical practice.
Crimini E; Repetto M; Aftimos P; Botticelli A; Marchetti P; Curigliano G
Cancer Treat Rev; 2021 Jul; 98():102223. PubMed ID: 34049187
[TBL] [Abstract][Full Text] [Related]
4. Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT).
Marret G; Bièche I; Dupain C; Borcoman E; du Rusquec P; Ricci F; Hescot S; Sablin MP; Tresca P; Bello D; Dubot C; Loirat D; Frelaut M; Lecerf C; Le Tourneau C; Kamal M
JCO Precis Oncol; 2021 Nov; 5():215-226. PubMed ID: 34994597
[TBL] [Abstract][Full Text] [Related]
5. Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan.
Chen BF; Tsai YF; Lien PJ; Lin YS; Feng CJ; Chen YJ; Cheng HF; Liu CY; Chao TC; Lai JI; Tseng LM; Huang CC
Breast Cancer; 2024 Mar; 31(2):217-227. PubMed ID: 38070067
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
[TBL] [Abstract][Full Text] [Related]
7. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
[TBL] [Abstract][Full Text] [Related]
8. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
[TBL] [Abstract][Full Text] [Related]
9. Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.
Mulet Margalef N; Castillo C; Mosteiro M; Pérez X; Aguilar S; Ruíz-Pace F; Gil M; Cuadra C; Ruffinelli JC; Martínez M; Losa F; Soler G; Teulé À; Castany R; Gallego R; Ruíz A; Garralda E; Élez E; Vivancos A; Tabernero J; Salazar R; Dienstmann R; Santos Vivas C
Mol Oncol; 2023 Sep; 17(9):1908-1916. PubMed ID: 37097008
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
Moreira A; Masliah-Planchon J; Callens C; Vacher S; Lecerf C; Frelaut M; Borcoman E; Torossian N; Ricci F; Hescot S; Sablin MP; Tresca P; Loirat D; Melaabi S; Trabelsi-Grati O; Pierron G; Gentien D; Bernard V; Vincent Salomon A; Servant N; Bieche I; Le Tourneau C; Kamal M
Eur J Cancer; 2019 Nov; 121():202-209. PubMed ID: 31593830
[TBL] [Abstract][Full Text] [Related]
11. Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients.
Hempel D; Ebner F; Garg A; Trepotec Z; Both A; Stein W; Gaumann A; Güttler L; Janni W; DeGregorio A; Hempel L; Milani V
Sci Rep; 2020 Jun; 10(1):10459. PubMed ID: 32591580
[TBL] [Abstract][Full Text] [Related]
12. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
13. Genetic alterations in sporadic triple negative breast cancer.
Pop LA; Cojocneanu-Petric RM; Pileczki V; Morar-Bolba G; Irimie A; Lazar V; Lombardo C; Paradiso A; Berindan-Neagoe I
Breast; 2018 Apr; 38():30-38. PubMed ID: 29202330
[TBL] [Abstract][Full Text] [Related]
14. Genomics to select treatment for patients with metastatic breast cancer.
Andre F; Filleron T; Kamal M; Mosele F; Arnedos M; Dalenc F; Sablin MP; Campone M; Bonnefoi H; Lefeuvre-Plesse C; Jacot W; Coussy F; Ferrero JM; Emile G; Mouret-Reynier MA; Thery JC; Isambert N; Mege A; Barthelemy P; You B; Hajjaji N; Lacroix L; Rouleau E; Tran-Dien A; Boyault S; Attignon V; Gestraud P; Servant N; Le Tourneau C; Cherif LL; Soubeyran I; Montemurro F; Morel A; Lusque A; Jimenez M; Jacquet A; Gonçalves A; Bachelot T; Bieche I
Nature; 2022 Oct; 610(7931):343-348. PubMed ID: 36071165
[TBL] [Abstract][Full Text] [Related]
15. Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer.
Hagio K; Amano T; Hayashi H; Takeshita T; Oshino T; Kikuchi J; Ohhara Y; Yabe I; Kinoshita I; Nishihara H; Yamashita H
Sci Rep; 2021 Apr; 11(1):8109. PubMed ID: 33854152
[TBL] [Abstract][Full Text] [Related]
16. ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers.
Adem C; Soderberg CL; Hafner K; Reynolds C; Slezak JM; Sinclair CS; Sellers TA; Schaid DJ; Couch F; Hartmann LC; Jenkins RB
Genes Chromosomes Cancer; 2004 Sep; 41(1):1-11. PubMed ID: 15236312
[TBL] [Abstract][Full Text] [Related]
17. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma.
Verdaguer H; Saurí T; Acosta DA; Guardiola M; Sierra A; Hernando J; Nuciforo P; Miquel JM; Molero C; Peiró S; Serra-Camprubí Q; Villacampa G; Aguilar S; Vivancos A; Tabernero J; Dienstmann R; Macarulla T
Clin Cancer Res; 2022 Apr; 28(8):1662-1671. PubMed ID: 35042699
[TBL] [Abstract][Full Text] [Related]
18. Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
Quaas A; Heydt C; Waldschmidt D; Alakus H; Zander T; Goeser T; Kasper P; Bruns C; Brunn A; Roth W; Hartmann N; Bunck A; Schmidt M; Buettner R; Merkelbach-Bruse S
BMC Gastroenterol; 2019 Feb; 19(1):21. PubMed ID: 30717682
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
Cejalvo JM; Pérez-Fidalgo JA; Ribas G; Burgués O; Mongort C; Alonso E; Ibarrola-Villava M; Bermejo B; Martínez MT; Cervantes A; Lluch A
Breast Cancer Res Treat; 2016 Nov; 160(1):69-77. PubMed ID: 27628192
[TBL] [Abstract][Full Text] [Related]
20. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
